Cargando…
The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
INTRODUCTION: Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about th...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095529/ https://www.ncbi.nlm.nih.gov/pubmed/34989830 http://dx.doi.org/10.1007/s00406-021-01368-3 |
_version_ | 1784705773340721152 |
---|---|
author | Fugger, Gernot Bartova, Lucie Fabbri, Chiara Fanelli, Giuseppe Dold, Markus Swoboda, Marleen Margret Mignon Kautzky, Alexander Zohar, Joseph Souery, Daniel Mendlewicz, Julien Montgomery, Stuart Rujescu, Dan Serretti, Alessandro Kasper, Siegfried |
author_facet | Fugger, Gernot Bartova, Lucie Fabbri, Chiara Fanelli, Giuseppe Dold, Markus Swoboda, Marleen Margret Mignon Kautzky, Alexander Zohar, Joseph Souery, Daniel Mendlewicz, Julien Montgomery, Stuart Rujescu, Dan Serretti, Alessandro Kasper, Siegfried |
author_sort | Fugger, Gernot |
collection | PubMed |
description | INTRODUCTION: Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about the real-world clinical correlates of patients primarily prescribed SSRIs in contrast to those receiving alternative first-line ADs. METHODS: These secondary analyses are based on a naturalistic, multinational cross-sectional study conducted by the European Group for the Study of Resistant Depression at ten research sites. We compared the socio-demographic and clinical characteristics of 1410 patients with primary MDD, who were either prescribed SSRIs or alternative substances as first-line AD treatment, using chi-squared tests, analyses of covariance, and logistic regression analyses. RESULTS: SSRIs were prescribed in 52.1% of MDD patients who showed lower odds for unemployment, current severity of depressive symptoms, melancholic features, suicidality, as well as current inpatient treatment compared to patients receiving alternative first-line ADs. Furthermore, patients prescribed SSRIs less likely received add-on therapies including AD combination and augmentation with antipsychotics, and exhibited a trend towards higher response rates. CONCLUSION: A more favorable socio-demographic and clinical profile associated with SSRIs in contrast to alternative first-line ADs may have guided European psychiatrists’ treatment choice for SSRIs, rather than any relevant pharmacological differences in mechanisms of action of the investigated ADs. Our results must be cautiously interpreted in light of predictable biases resulting from the open treatment selection, the possible allocation of less severely ill patients to SSRIs as well as the cross-sectional study design that does not allow to ascertain any causal conclusions. |
format | Online Article Text |
id | pubmed-9095529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-90955292022-05-13 The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries Fugger, Gernot Bartova, Lucie Fabbri, Chiara Fanelli, Giuseppe Dold, Markus Swoboda, Marleen Margret Mignon Kautzky, Alexander Zohar, Joseph Souery, Daniel Mendlewicz, Julien Montgomery, Stuart Rujescu, Dan Serretti, Alessandro Kasper, Siegfried Eur Arch Psychiatry Clin Neurosci Original Paper INTRODUCTION: Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about the real-world clinical correlates of patients primarily prescribed SSRIs in contrast to those receiving alternative first-line ADs. METHODS: These secondary analyses are based on a naturalistic, multinational cross-sectional study conducted by the European Group for the Study of Resistant Depression at ten research sites. We compared the socio-demographic and clinical characteristics of 1410 patients with primary MDD, who were either prescribed SSRIs or alternative substances as first-line AD treatment, using chi-squared tests, analyses of covariance, and logistic regression analyses. RESULTS: SSRIs were prescribed in 52.1% of MDD patients who showed lower odds for unemployment, current severity of depressive symptoms, melancholic features, suicidality, as well as current inpatient treatment compared to patients receiving alternative first-line ADs. Furthermore, patients prescribed SSRIs less likely received add-on therapies including AD combination and augmentation with antipsychotics, and exhibited a trend towards higher response rates. CONCLUSION: A more favorable socio-demographic and clinical profile associated with SSRIs in contrast to alternative first-line ADs may have guided European psychiatrists’ treatment choice for SSRIs, rather than any relevant pharmacological differences in mechanisms of action of the investigated ADs. Our results must be cautiously interpreted in light of predictable biases resulting from the open treatment selection, the possible allocation of less severely ill patients to SSRIs as well as the cross-sectional study design that does not allow to ascertain any causal conclusions. Springer Berlin Heidelberg 2022-01-06 2022 /pmc/articles/PMC9095529/ /pubmed/34989830 http://dx.doi.org/10.1007/s00406-021-01368-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Fugger, Gernot Bartova, Lucie Fabbri, Chiara Fanelli, Giuseppe Dold, Markus Swoboda, Marleen Margret Mignon Kautzky, Alexander Zohar, Joseph Souery, Daniel Mendlewicz, Julien Montgomery, Stuart Rujescu, Dan Serretti, Alessandro Kasper, Siegfried The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries |
title | The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries |
title_full | The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries |
title_fullStr | The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries |
title_full_unstemmed | The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries |
title_short | The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries |
title_sort | sociodemographic and clinical profile of patients with major depressive disorder receiving ssris as first-line antidepressant treatment in european countries |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095529/ https://www.ncbi.nlm.nih.gov/pubmed/34989830 http://dx.doi.org/10.1007/s00406-021-01368-3 |
work_keys_str_mv | AT fuggergernot thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT bartovalucie thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT fabbrichiara thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT fanelligiuseppe thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT doldmarkus thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT swobodamarleenmargretmignon thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT kautzkyalexander thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT zoharjoseph thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT souerydaniel thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT mendlewiczjulien thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT montgomerystuart thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT rujescudan thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT serrettialessandro thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT kaspersiegfried thesociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT fuggergernot sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT bartovalucie sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT fabbrichiara sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT fanelligiuseppe sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT doldmarkus sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT swobodamarleenmargretmignon sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT kautzkyalexander sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT zoharjoseph sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT souerydaniel sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT mendlewiczjulien sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT montgomerystuart sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT rujescudan sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT serrettialessandro sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries AT kaspersiegfried sociodemographicandclinicalprofileofpatientswithmajordepressivedisorderreceivingssrisasfirstlineantidepressanttreatmentineuropeancountries |